A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest.

ABSTRACT:

Background

Currently, prognostication for pancreatic ductal adenocarcinoma (PDAC) is based upon a coarse clinical staging system. Thus, more accurate prognostic tests are needed for PDAC patients to aid treatment decisions.

Methods and findings

Affymetrix gene expression profiling was carried out on 15 human PDAC tumors and from the data we identified a 13-gene expression signature (risk score) that correlated with patient survival. The gene expression risk score was then independently validated using published gene expression data and survival data for an additional 101 patients with pancreatic cancer. Patients with high-risk scores had significantly higher risk of death compared to patients with low-risk scores (HR 2.27, p = 0.002). When the 13-gene score was combined with

SUBMITTER: Newhook TE 

PROVIDER: S-EPMC4152146 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature